Benign Prostatic Hyperplasia BPH presenting with lower urinary tract symptoms LUTS and bladder outlet obstruction BOO Benign Prostatic Hyperplasia Prostate Prostatic Hyperplasia Lower Urinary Tract Symptoms Urinary Bladder Neck Obstruction Urinary Retention Ultrasonography Prostate Specific Antigen Adrenergic alpha Antagonists Tamsulosin
Conditions
Interventions
Single group of 100 male patients aged 40 to 80 years with lower urinary tract symptoms due to benign prostatic hyperplasia, having enlarged prostate on clinical exam or ultrasound and no absolute ind
Diagnostic
LUTS due to BPH receiving tamsulosin
Sponsors
University College of Medical Sciences (University of Delhi), Delhi-110095
Eligibility
Sex/Gender
Male
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1 Males aged 40 to 80 years who give informed consent 2 LUTS due to BPH with no absolute indication for surgery 3 Enlarged prostate on clinical exam or ultrasound
Exclusion criteria
Exclusion criteria: 1 Mental disorders or illness preventing understanding or compliance with protocol 2 Known allergy or contraindication to tamsulosin 3 Prior prostate surgery or diagnosed carcinoma prostate 4 BOO due to causes other than BPH 5 BPH with neurogenic bladder, urethral stricture, or vesical stones 6 Previous use of medications affecting storage or voiding alpha blockers, 5 alpha reductase inhibitors, anticholinergics, etc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between intravesical prostatic protrusion IPP and clinical parameters of bladder outlet obstruction BOO Baseline and up to 2 months Measurement of IPP on transabdominal ultrasound and correlation with IPSS, uroflowmetry parameters, post void residual, prostate volume | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in International Prostate Symptom Score IPSS Baseline and every 2 weeks up to 2 months IPSS questionnaire score,Peak flow rate Qmax Baseline and every 2 weeks up to 2 months Uroflowmetry,Safety of tamsulosin At each follow up visit and at 2 months Monitoring of adverse events, adverse drug reactions, side effects, lab tests LFT KFT hemogram | — |
Countries
India
Contacts
Public ContactIqbal Singh
University College of Medical Sciences (University of Delhi) & Guru Teg Bahadur Hospital
Outcome results
None listed